Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation
Atrial fibrillation (AF) is a growing health problem that increases morbidity and mortality, and in most patients progresses to more advanced diseases over time. Recent research has examined the underlying mechanisms, risk factors, and progression of AF, leading to updated AF disease classification...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/13/3/679 |
| _version_ | 1797318594097315840 |
|---|---|
| author | Christopher X. Wong Eric F. Buch Ramin Beygui Randall J. Lee |
| author_facet | Christopher X. Wong Eric F. Buch Ramin Beygui Randall J. Lee |
| author_sort | Christopher X. Wong |
| collection | DOAJ |
| description | Atrial fibrillation (AF) is a growing health problem that increases morbidity and mortality, and in most patients progresses to more advanced diseases over time. Recent research has examined the underlying mechanisms, risk factors, and progression of AF, leading to updated AF disease classification schemes. Although endocardial catheter ablation is effective for early-stage paroxysmal AF, it consistently achieves suboptimal outcomes in patients with advanced AF. Identification of the factors that lead to the increased risk of treatment failure in advanced AF has spurred the development and adoption of hybrid ablation therapies and collaborative heart care teams that result in higher long-term arrhythmia-free survival. Patients with non-paroxysmal AF, atrial remodeling, comorbidities, or AF otherwise deemed difficult to treat may find hybrid treatment to be the most effective option. Future research of hybrid therapies in advanced AF patient populations, including those with dual diagnoses, may provide further evidence establishing the safety and efficacy of hybrid endo-epicardial ablation as a first line treatment. |
| first_indexed | 2024-03-08T03:54:35Z |
| format | Article |
| id | doaj.art-550c424994ea4cfd819828541f72cf9f |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-08T03:54:35Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-550c424994ea4cfd819828541f72cf9f2024-02-09T15:15:33ZengMDPI AGJournal of Clinical Medicine2077-03832024-01-0113367910.3390/jcm13030679Hybrid Endo-Epicardial Therapies for Advanced Atrial FibrillationChristopher X. Wong0Eric F. Buch1Ramin Beygui2Randall J. Lee3Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide 5001, AustraliaCardiac Arrhythmia Center, University of California Los Angeles, Los Angeles, CA 90095, USACardiothoracic Surgery, University of California San Francisco, San Francisco, CA 94143, USACardiac Electrophysiology, University of California San Francisco, San Francisco, CA 94143, USAAtrial fibrillation (AF) is a growing health problem that increases morbidity and mortality, and in most patients progresses to more advanced diseases over time. Recent research has examined the underlying mechanisms, risk factors, and progression of AF, leading to updated AF disease classification schemes. Although endocardial catheter ablation is effective for early-stage paroxysmal AF, it consistently achieves suboptimal outcomes in patients with advanced AF. Identification of the factors that lead to the increased risk of treatment failure in advanced AF has spurred the development and adoption of hybrid ablation therapies and collaborative heart care teams that result in higher long-term arrhythmia-free survival. Patients with non-paroxysmal AF, atrial remodeling, comorbidities, or AF otherwise deemed difficult to treat may find hybrid treatment to be the most effective option. Future research of hybrid therapies in advanced AF patient populations, including those with dual diagnoses, may provide further evidence establishing the safety and efficacy of hybrid endo-epicardial ablation as a first line treatment.https://www.mdpi.com/2077-0383/13/3/679atrial fibrillationleft atrial appendagecatheter ablationhybrid AF procedurepulmonary vein isolation |
| spellingShingle | Christopher X. Wong Eric F. Buch Ramin Beygui Randall J. Lee Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation Journal of Clinical Medicine atrial fibrillation left atrial appendage catheter ablation hybrid AF procedure pulmonary vein isolation |
| title | Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation |
| title_full | Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation |
| title_fullStr | Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation |
| title_full_unstemmed | Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation |
| title_short | Hybrid Endo-Epicardial Therapies for Advanced Atrial Fibrillation |
| title_sort | hybrid endo epicardial therapies for advanced atrial fibrillation |
| topic | atrial fibrillation left atrial appendage catheter ablation hybrid AF procedure pulmonary vein isolation |
| url | https://www.mdpi.com/2077-0383/13/3/679 |
| work_keys_str_mv | AT christopherxwong hybridendoepicardialtherapiesforadvancedatrialfibrillation AT ericfbuch hybridendoepicardialtherapiesforadvancedatrialfibrillation AT raminbeygui hybridendoepicardialtherapiesforadvancedatrialfibrillation AT randalljlee hybridendoepicardialtherapiesforadvancedatrialfibrillation |